One ARK Invest exchange-traded fund run by ETF star Cathie Wood bought over 150,000 shares of Robinhood Markets Inc. (NASDAQ: HOOD) on Tuesday, The price of this ETF was up around 2% in Tuesday’s session, and the fund is up a fair amount in the past year.
ARK Fintech Innovation ETF (NYSEARCA: ARKF) bought 151,697 shares of Robinhood. At Tuesday’s closing price, this would have valued this purchase at roughly $6.4 million. This is only a small fraction of the total holdings. The ETF is up roughly 20% in the past year.
Check out all of ARK Invest’s buys for Tuesday:
| Fund | Ticker | Name | Shares |
|---|---|---|---|
| ARKF | TOST | TOAST | 33,388 |
| ARKF | HOOD | ROBINHOOD MARKETS | 151,697 |
| ARKF | PATH | UIPATH | 243,301 |
| ARKG | SURF | SURFACE ONCOLOGY | 188,676 |
| ARKG | SLGC | SOMALOGIC | 80,200 |
| ARKG | SGFY | SIGNIFY HEALTH | 391,069 |
| ARKG | QSI | QUANTUM-SI | 119,754 |
| ARKG | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA | 124,974 |
| ARKG | MASS | 908 DEVICES | 18,000 |
| ARKG | DYNS | DYNAMICS SPECIAL PURPOSE | 204 |
| ARKG | ADPT | ADAPTIVE BIOTECHNOLOGIES | 105,175 |
| ARKG | BEAM | BEAM THERAPEUTICS | 12,094 |
| ARKK | TWOU | 2U | 132,665 |
| ARKK | TDOC | TELADOC HEALTH | 154,175 |
| ARKK | SSYS | STRATASYS | 26,693 |
| ARKK | SGFY | SIGNIFY HEALTH | 358,048 |
| ARKK | PACB | PACIFIC BIOSCIENCES OF CALIFORNIA | 658,606 |
| ARKK | DNA | GINKGO BIOWORKS | 188,902 |
| ARKK | BEAM | BEAM THERAPEUTICS | 92,397 |
| ARKQ | VLD | VELO3D | 38,569 |
| ARKQ | NIU | NIU TECHNOLOGIES | 2,300 |
| ARKQ | MKFG | MARKFORGED | 141,418 |
| ARKQ | BLDE | BLADE AIR MOBILITY | 61,699 |
| ARKQ | ACHR | ARCHER AVIATION | 80,143 |
| ARKW | VUZI | VUZIX | 48,009 |
| ARKW | TWOU | 2U | 33,762 |
| ARKW | SQ | SQUARE | 35,194 |
| ARKX | BLDE | BLADE AIR MOBILITY | 3,733 |
| ARKX | PATH | UIPATH | 52,252 |
| ARKX | PRNT | 3D PRINTING ETF | 19,765 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of a673b.bigscoots-temp.com.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
